Retatrutide
Price range: $55.00 through $135.00
Up to 8% offRetatrutide is an investigational peptide studied for how three hormone pathways—GIP, GLP-1, and glucagon—work together to influence metabolism and energy balance.
Description
Retatrutide is a newer synthetic peptide designed to activate three receptors at the same time: GIP, GLP-1, and glucagon. Researchers are studying this combination to understand how these pathways work together in metabolic regulation, including blood-sugar and energy-balance processes.
Clinical research has examined retatrutide’s effects on body weight, glucose regulation, and other metabolic outcomes, but it remains an investigational compound rather than an approved finished drug.
Research Areas
- GIP receptor signalling
- GLP-1 receptor signalling
- Glucagon receptor signalling
- Metabolic regulation
- Energy-balance research
- Multi-receptor pharmacology
Product Highlights
- Triple-receptor research peptide
- Supplier COA available
- Lot-specific documentation
- Lyophilized research material
Research Use Notice
For laboratory research only. Not for human or veterinary use. Retatrutide is investigational and is not an approved finished therapeutic product.
Technical Specifications
| Specification | Value |
|---|---|
| Product | Retatrutide |
| Alternate Identifier | LY3437943 |
| Classification | Triple GIP / GLP-1 / glucagon receptor research peptide |
| CAS | 2381089-83-2 |
| Molecular Weight | ~4731 g/mol |
| Form | Lyophilized powder |
| Intended Use | Laboratory research |
Literature
What researchers are studying
Retatrutide research focuses on how simultaneous activation of GIP, GLP-1, and glucagon receptors changes metabolic signalling. Clinical studies have evaluated its effects on body weight and metabolic markers, while mechanistic research continues to examine how the three pathways interact.
Selected Literature
- Phase 2 clinical research on retatrutide — NEJM View NEJM publication
- Ongoing metabolic and multi-receptor research — PubMed View PubMed publication
COA Documentation
This trial lot is qualified using supplier documentation and the supplier-provided lot-specific COA. Independent Canadian laboratory confirmation has not been completed.
Frequently Asked Questions
Key information about retatrutide, its research targets, investigational status, documentation, and intended use.
Retatrutide is a synthetic investigational peptide designed to activate three metabolic hormone receptors: GIP, GLP-1, and glucagon receptors.
Retatrutide is designed to activate GIP, GLP-1, and glucagon receptors.
Researchers are studying whether simultaneous activation of three metabolic receptor pathways produces different biological and metabolic effects from compounds that target only one or two of those pathways.
No. Retatrutide remains an investigational compound and is being studied in clinical research.
Yes. Supplier-provided Certificate of Analysis documentation may be available for the applicable lot.
No. This product is intended for laboratory research purposes only and is not intended for human use.
Additional information
| Size | 5 mg, 10 mg, 20 mg |
|---|
Reviews